Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on ...(mg had an increase in HDL of 19.0 percen...),Health

Date:5/31/2008

mg had an increase in HDL of 19.0 percent and decrease in triglycerides of 42.9 percent compared to 10.3 percent and 25.6 percent, respectively, with rosuvastatin 20mg monotherapy. LDL decreased 38.8 percent with the combination compared to 6.5 percent with TriLipix 135mg monotherapy.

TriLipix Clinical Development Program

TriLipix was studied alone and in combination with three of the most commonly prescribed statins (atorvastatin, simvastatin and rosuvastatin) in 2,698 patients with mixed dyslipidemia. The clinical program also includes a 52-week, long-term, open-label extension study. More than 2,200 patients were treated with TriLipix in combination with statins across the four studies.

"This broad clinical trial program for TriLipix provides physicians with a wealth of data supporting a potential new treatment option to help manage lipids," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.

About TriLipix (ABT-335)

TriLipix is an investigational new fenofibric acid molecule, currently in clinical development for treating patients with unhealthy lipid levels, including LDL cholesterol, triglycerides and HDL cholesterol. A New Drug Application (NDA) for TriLipix for use as monotherapy and in combination with statins has been submitted to the U.S. Food and Drug Administration (FDA). Abbott and AstraZeneca are working together to co-develop and market a fixed-dose combination of TriLipix and CRESTOR. The companies plan to submit an NDA to the FDA in 2009.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals,
'/>"/>

SOURCE Abbott Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients